Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Eur J Clin Nutr ; 69(11): 1209-14, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25828621

ABSTRACT

BACKGROUND/OBJECTIVES: Lipid-lowering and anti-inflammatory effects have been individually described for tocotrienols (TTs) and polymethoxylated flavones (PMFs). This study investigated low-density lipoprotein-cholesterol (LDL-C)- and high-sensitivity C-reactive protein (hsCRP)-reducing effects of combined TT-PMF treatment in low doses in hypercholesterolemic individuals with subclinical inflammation. SUBJECTS/METHODS: In the double-blind, placebo-controlled study, 240 Caucasians with LDL-C ⩾3.36 mmol/l and hsCRP ⩾1 mg/l were enrolled and randomized into group S1 (12 mg/day TT and 103 mg/day PMF), group S2 (27 mg/day TT and 32 mg/day PMF) or placebo. RESULTS: Twenty-three subjects dropped out of the study, 13 were excluded from the analysis because of lack of compliance. A total of 204 subjects per-protocol analysis were included. After 12 weeks of treatment, no significant differences in LDL-C levels (primary outcome) were observed between groups. LDL-C levels significantly decreased in all intervention groups (S1: -5.2%, S2: -4.8% and P: -4.2%). Total cholesterol and hsCRP (secondary outcome) did not change significantly. CONCLUSIONS: PMF-TT supplements had no effect beyond that of placebo on elevated LDL-C and hsCRP levels.


Subject(s)
C-Reactive Protein/metabolism , Cholesterol, LDL/blood , Citrus/chemistry , Flavones/pharmacology , Hypercholesterolemia/blood , Plant Oils/pharmacology , Tocotrienols/pharmacology , Aged , Arecaceae/chemistry , Double-Blind Method , Female , Fruit/chemistry , Humans , Hypercholesterolemia/drug therapy , Hypercholesterolemia/pathology , Inflammation/etiology , Male , Middle Aged , Palm Oil , Plant Extracts/pharmacology , Plant Oils/chemistry
2.
Article in English | MEDLINE | ID: mdl-21862301

ABSTRACT

Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01g EPA+0.67g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.


Subject(s)
Docosahexaenoic Acids/therapeutic use , Dyslipidemias/drug therapy , Eicosapentaenoic Acid/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Triglycerides/blood , Adult , Aged , Analysis of Variance , Biological Availability , Docosahexaenoic Acids/pharmacokinetics , Double-Blind Method , Eicosapentaenoic Acid/pharmacokinetics , Female , Humans , Hypolipidemic Agents/therapeutic use , Male , Middle Aged , Patient Compliance , Treatment Outcome
3.
Eur J Clin Nutr ; 65(2): 247-54, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21063431

ABSTRACT

BACKGROUND: There is a debate currently about whether different chemical forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are absorbed in an identical way. The objective of this study was to investigate the response of the omega-3 index, the percentage of EPA+DHA in red blood cell membranes, to supplementation with two different omega-3 fatty acid (n-3 FA) formulations in humans. DESIGN: The study was conducted as a double-blinded placebo-controlled trial. A total of 150 volunteers was randomly assigned to one of the three groups: (1) fish oil concentrate with EPA+DHA (1.01 g+0.67 g) given as reesterified triacylglycerides (rTAG group); (2) corn oil (placebo group) or (3) fish oil concentrate with EPA+DHA (1.01 g+0.67 g) given as ethyl ester (EE group). Volunteers consumed four gelatine-coated soft capsules daily over a period of six months. The omega-3 index was determined at baseline (t(0)) after three months (t(3)) and at the end of the intervention period (t(6)). RESULTS: The omega-3 index increased significantly in both groups treated with n-3 FAs from baseline to t(3) and t(6) (P<0.001). The omega-3 index increased to a greater extent in the rTAG group than in the EE group (t(3): 186 versus 161% (P<0.001); t(6): 197 versus 171% (P<0.01)). CONCLUSION: A six-month supplementation of identical doses of EPA+DHA led to a faster and higher increase in the omega-3 index when consumed as triacylglycerides than when consumed as ethyl esters.


Subject(s)
Docosahexaenoic Acids/pharmacokinetics , Eicosapentaenoic Acid/pharmacokinetics , Esters/pharmacokinetics , Fatty Acids, Omega-3/blood , Triglycerides/pharmacokinetics , Adult , Aged , Biological Availability , Dietary Fats, Unsaturated/pharmacokinetics , Dietary Supplements , Double-Blind Method , Female , Fish Oils , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL